Background. Those taking proton pump inhibitors (PPIs) might have a higher risk of acute kidney injury. The long-term safety, especially the PPI-associated chronic kidney disease (CKD) is the subsequent concern. Objective. This study explores the potential relationship between using PPIs and CKD in Taiwan. Methods. Using a database collated by the Taiwan National Health Insurance programme, we conducted a population-based case-controlled study to identify 16 704 cases of patients aged 20 years or older with newly diagnosed CKD between 2000 and 2013. 16 704 controls were randomly selected and were matched by sex, age and comorbidities. 'Use' of PPIs was defined as when subjects had received at least a prescription for PPIs before the index date. 'Non-use' was defined as subjects who had never received a prescription for PPIs before the index date. The odds ratio (OR) for CKD associated with the use of PPIs was estimated by a logistic regression model. Results. The OR for CKD was 1.41 for subjects using PPIs [95% confidence interval (CI) 1.34, 1.48] compared with subjects who had never used PPIs. Almost all major types of PPIs present a weak association with increased odds of CKD in cumulative duration and dosage regression analysis. The OR in relation to cumulative duration (per month) of PPIs use was 1.02 (95% CI 1.01, 1.02) and the OR in relation to cumulative dosage (per microgram) of PPIs use was 1.23 (95% CI 1.18, 1.28). Conclusions. Using PPIs presented 1.4-fold higher odds of CKD in Taiwan health insurance claims data analysis.
Introduction
Chronic kidney disease (CKD) is a persistent global issue. Ever since the Kidney Disease: Improving Global Outcomes (KDIGO) organization released its clinical practice guideline for the evaluation and management of CKD in 2002 and 2012 (1) , the number of commentaries and discussions pertaining to the evaluation and management of patients with CKD has been steadily rising, from both occidental and oriental regions. The economic impact of CKD is excessive and includes both direct and indirect medical costs and other non-medical social costs. However, despite such economic impact, the quality of care for patients with CKD remains insufficient. Recent governmental efforts have succeeded in improving the care of patients with CKD and have reduced the incidence of end-stage renal disease (ESRD) in Taiwan (2) . However, Taiwan still has the highest annual incidence and prevalence of ESRD, followed by the USA and Japan (3) .
Globally, diabetes mellitus and hypertension were initially thought to be the major causes of CKD. However, other risk factors remain unknown (3) . Compared with patients with diabetes and hypertension, the gap between the prevalence and awareness of CKD in the general population has made it very difficult to prevent CKD. Medication is one of the most important considerations when evaluating patients with CKD. When CKD progression is noted, the prescription of potentially nephrotoxic and renal-excreted drugs should be used very cautiously (1) .
Proton pump inhibitors (PPIs) have been marketed for decades. Exhibiting effectiveness and safety without immediate, severe or large-scale adverse events, PPIs are now one of the most popular medications used to treat gastric acid-related diseases. However, the adverse effects of using PPIs over longer time periods are now becoming evident. Since PPIs cause the suppression of gastric acid, it follows that vitamin and mineral absorption may be compromised. Patients using PPIs might also have a higher risk of pneumonia and other infectious diseases, along with an increased risk of hip, wrist and spine fractures (4) . Since almost all PPIs are metabolized by the liver, the potential burden of these drugs upon the renal system was not initially evident or considered (5) .
Following a series of case reports describing the association between PPIs and acute interstitial nephritis (6,7), Leonard et al. (8) conducted two retrospective case-controlled studies raising the suspicions of an association between PPIs and acute kidney injury; however, these associations were not confirmed. In 2015, Antoniou et al. (9) analysed a population-based cohort of elderly subjects in Ontario and showed that those taking PPIs had a higher risk of acute kidney injury and acute interstitial nephritis. CKD might develop gradually without being noted or may represent a sequence of acute kidney injury without full recovery.
PPI-associated CKD was the subsequent concern. In 2016, three studies were reported that aimed to demonstrate an association between the use of PPIs and CKD. These studies took place in the USA, which is an occidental region (10) (11) (12) . Since the incidence and prevalence of CKD are different across different races and countries (11), we are very interested in determining the relationship between PPI use and CKD in oriental areas, especially Taiwan, with the highest annual incidence and prevalence of ESRD. We therefore conducted this present population-based case-controlled study to investigate the potential association between PPI use and the risk of CDK in Taiwan.
Methods

Data source
Taiwan is an independent country with a population exceeding 23 million people. We conducted a population-based case-controlled study using data accrued from people enrolled in the Taiwan National Health Insurance (NHI) programme. This insurance programme is the only government-run universal health insurance programme commenced in March 1995 and now covers 99% of the entire population living in Taiwan (13) . This dataset consisted of claims data of 1million people randomly selected from the all 23 million insured individuals based on year 2000 population. Once individuals were anonymized, we collated patient demographic variables and medical records were collected for data analysis, avoiding the potential violation of patient privacy at all times.
Participants
According to the database of International Classification of Diseases (Ninth Revision, Clinical Modification; ICD-9-CM), we identified cases of patients aged 20 to 84 years with newly diagnosed CKD (ICD-9 code 585-586) from 2000 to 2013. The very first diagnosis date of CKD was defined as the index date. Subjects who did not have the diagnosis code of CKD were randomly selected from the same database as controls. Both cases and controls were matched by sex, age (per 5 years), comorbidities and the index year of CKD diagnosis ( Supplementary Fig. 1 ). To decrease the worrisome and anxiety of time related bias, patients who had undertaken renal replacement therapy were also excluded in our analysis.
Comorbidities before the index date that could be potentially related to CKD were included as follows: alcohol-related disease (ICD-9 
Measurements of the use of PPIs, histamine-2 receptor antagonists and non-steroid anti-inflammation drugs
We included all PPIs available in Taiwan from 2000 to 2013, such as esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. The 'use' of medications was defined as subjects who had at least one medication prescription before the index date. The 'nonuse' of medications was defined as subjects who never had any medication prescriptions in clinics before the index date.
We also included the prescription history of histamine-2 receptor antagonists and non-steroid anti-inflammation drugs (NSAIDs) and matched them in cases and controls because histamine-2 receptor antagonists are usually used in patients with similar indications, and, NSAIDs are known to cause renal toxicity. Both PPIs and histamine-2 receptor antagonists are not legally available over the counter without a physician's prescription.
Statistical analysis
We first compared the distribution of demographic status, PPIs use, histamine-2 receptor antagonist use and comorbidities between the cases and controls using a chi-square test for categorized variables to present the distribution of PPIs use between the cases and controls and to confirm the successful matches of sex, age and comorbidities between cases and controls. The student's t-test was then used to test the difference of mean age and mean duration of exposure to PPIs between the cases and the controls. A conditional logistic regression model was also used to measure the odds ratio (OR) and 95% confidence interval (CI) for the association between CKD and PPI use. Finally, we conducted an analysis on the dose-related response and duration-related response for PPIs use.
All analyses were performed using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC) and results were considered statistically significant when two-tailed P-values were less than 0.05.
Results
Characteristics of the study population
Initially, 17.424 newly diagnosed CKD patients were identified in the dataset. After excluding subjects without matched control (n = 720), 16 704 cases remained in case group for final analysis. Table 1 showed 16 704 cases of newly diagnosed CKD from 2000 to 2013 along with 16 704 controls without CKD. Cases and controls had similar distributions of sex and age. The mean age (SD) was 64.3 (13.0) years in cases of patients with CKD and was 64.3 (12.9) years in controls, without statistical significance (t-test, P = 0.85). The mean duration of PPI exposure (SD) was 4.02 (7.11) months in cases of patients with CKD and 4.03 (7.24) months in controls, without statistical significance (t-test, P = 0.98). Cases of patients with CKD were more likely to have a higher proportion of PPI use than controls (29.8% versus 23.1%, chi-square test, P < 0.001). Cases of patients with CKD were also more likely to have a higher proportion of NSAIDs use than controls (96.3% versus 95.7%, chi-square test, P = 0.01). Since other factors were all controlled, there was no significant difference in the use of histamine-2 receptor antagonists (chi-square test, P = 0.92) or other comorbidities between the cases and controls (chi-square test, P > 0.05) ( Table 1) .
CDK associated with PPI use
A conditional logistic regression model revealed that the OR of CKD was 1.42 for subjects using PPIs (95% CI 1.35, 1.49) compared with subjects who had not used PPIs (Table 2) .
We next demonstrated the effect of the cumulative duration of PPI use and CKD in a logistic regression model (Table 3 ). The risk of CKD was higher after a month of PPIs use (OR 1.02) compared with that without PPI use (95% CI 1.01, 1.02). The calculated OR for CKD was 1.02 (95% CI 1.01, 1.03) in patients using esomeprazole per month, 1.03 (95% CI 1.01, 1.04) in those using lansoprazole per month, 1.03 (95% CI 1.02, 1.04) in those using omeprazole per month, 1.04 (95% CI 1.02, 1.06) in those using pantoprazole per month and 1.02 (95% CI 0.99, 1.05) in those using rabeprazole per month. The cumulative dose effect has been shown in Table 4 
Discussion
In our population-based case-controlled study, we clearly demonstrated that PPI use was associated with an increasing risk of CKD with a dose-response effect. We also found that the longer the patient used PPIs, the higher the risk the patient would have of being diagnosed with CKD. To the best of our knowledge, this represents the first population-based study using national health insurance claims data to explore the association between PPIs use and an increasing risk of CKD in the oriental region. In contrast to other case control study conducted by Peng et al. (14) , which targeted the patients with CKD who progressed to ESRD, our study demonstrated the occurrence of CKD in previously healthy individuals with the use of PPIs.
As mentioned earlier, we carried out a PubMed search on 1 February 2017, with Medical Subject Headings (MeSH), using PPI and 'Renal Insufficiency, Chronic (CKD)' as keywords. We identified three qualified epidemiological studies focusing upon the association of PPIs use and CKD development. By analysing data arising from adults (45-65 years of age) from four communities in different states in the Atherosclerosis Risk in Community (ARIC) study, and another replication cohort from a large rural health-care system in the USA, Lazarus et al. (11) concluded that PPI use was associated with a higher risk of CKD with a hazard ratio (HR) of 1.17 (95% CI 1.12, 1.23) to 1.50 (95% CI 1.14, 1.96) in different analysis models. The other two studies were both based upon the dataset compiled by the US Department of Veterans Affairs. Using adjusted Cox survival models, Xie et al. (12) demonstrated that PPI use had an increased risk of CKD with an HR of 1.28 (95% CI 1.23, 1.34) when compared with the use of histamine-2 receptor antagonists. Combining data from the two different cohorts, we performed a meta-analysis and calculated that the overall HR was 1.31 (95% CI 1.18, 1.45) (Fig. 1) .
Furthermore, the case-controlled study using data compiled by the Upstate New York Network conducted by Arora et al. (10) also revealed higher odds (OR 1.10) for the development of CKD. To decrease the possible immortal time bias effect when analysing health insurance claims dataset, we also decided to conduct this PPIs and CKD association observation study in case control design.
CKD is defined as abnormalities of kidney structure or function presenting for more than 3 months. Clinically, CKD would be considered and diagnosed when the glomerular filtration rate is reduced to less than 60 ml/min/1.73 m 2 and/or if there is evidence of albuminuria, urine sediment abnormalities, electrolytes and other abnormalities owing to tubular disorders or if there are structural abnormalities detected by imaging (1). The mechanism regarding how PPIs use can induce CKD is likely to be complicated and may not only involve one single pathway. The most common cause is now considered to be acute interstitial nephritis residual sequelae with a lower glomerular filtration rate than the base line prior to PPIs exposure (15) . Muriithi et al. (16) conducted a case-series study and reported that acute interstitial nephritis was mostly caused by drugs; these authors also reported that omeprazole, a type of PPIs, was one of the most recognized single medicines. At the same time, only 49% of patients with drug-induced acute tubular necrosis treated with steroids achieved complete recovery, and a longer exposure and delayed diagnosis might render PPI-induced acute interstitial nephritis more likely to progress to CKD (17) .
However, indication bias should also be considered. PPIs were indicated for patients with upper gastro-enteric bleeding. Compared with placebo or histamine-2 receptor antagonists, the use of PPIs in patients with bleeding peptic ulcers might reduce re-bleeding rates and surgical intervention. A higher dose of PPIs might be applied to prevent recurrent bleeding in hypovolaemic shock patients with renal hypoperfusion who were also at risk of CKD (17) .
The risk of infections and inflammations in patients taking PPIs might also partially contribute to the development of CKD in PPI cases. NSAIDs might induce peptic ulcers, and such patients might therefore have a higher chance of being prescribed with histamine-2 receptor antagonists and PPIs. At the same time, NSAIDs are also notorious for their renal toxicity. Even though Nderitu et al. (18) concluded that the avoidance of NSAIDs in the medium term is unnecessary in patients with moderate to severe CKD, the use of NSAIDs as an independent risk factor for CKD was confirmed in patients with hypertension in a nationwide longitudinal cohort study (19) . However, a previous report conducted by Lazarus et al. (11) in which the use of NSAIDs was also included in analyses, Table 3 . Odds ratio and 95% CI of CKD in relation to the cumulative duration of proton pump inhibitor use by a logistic regression model the association between PPIs use and higher risk of incident CKD remained. In our study, we matched the use of histamine-2 receptor antagonists and NSAIDs to contrast the association between the use of PPIs and CKD. In oriental areas, Using Chinese traditional herbs and medicines might also be one of the other potential confounders; Su et al. (20) conducted a cross-sectional survey and demonstrated that the regular use of nephrotoxic medications was an independent risk factor for CKD in China. There were, however, several limitations to our current study. For example, we were unable to include patient lifestyle data, such as cigarette-smoking habits and alcohol consumption, recreating drug use, socioeconomic status, or details regarding the patient's living environment. Several other factors relating to physical examinations and laboratory studies were also unavailable, including heart rate, uric acid, estimated glomerular infiltration rate and the severity of albuminuria. Consequently, we could not determine the stage of CKD for each subject. Other potential factors, such as low birth weight, family history obstructive sleep apnea, and periodontal disease, were also not defined in our study. Furthermore, we could not ensure that all prescribed medications were taken by patients after leaving their clinics, but with this large population-based study, we can assume that the compliance of cases and controls were similar. There were also some concerns over miscoding when using claims data for analysis. At the same time, although our study reported that the association between the use of PPIs and CKD was reliable, its extrapolation to the oriental population living in western countries and/or other ethnic population living in eastern countries was limited.
Despite the inherent limitations, there was significant strength in our present study. PPIs are not legally available over the counter without a physician's prescription. With good accessibility and the low cost for individuals holding National Health Insurance in Taiwan, our study was of robust design and our analysis reliable. A significant association between the cumulative duration and dosage of PPIs use and CKD was clearly evident. Dose-and durationdependent effect of PPIs use and CKD development has also been reported in previous reports (11, 12) . Although previously believed to be safe and without obvious adverse effects, the use of PPIs, especially when used inappropriately and over long time periods, should now be reappraised from both patients' and physicians' points of view (21) .
Conclusion
Using PPIs presented 1.4-fold higher odds of CKD in Taiwan health insurance claims data analysis. Almost all individual PPIs, including esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole, are potentially associated with an increased odds of CDK. Further long-term prospective study also collecting the detailed physical and laboratory examination data to demonstrate the CKD evolving due to PPI exposure is needed to confirm the association.
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